The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays

Durham, Brian H.; Joseph, Frank; Bailey, Lisa M.; Fraser, William D.
September 2007
Annals of Clinical Biochemistry;Sep2007, Vol. 44 Issue 5, p463
Academic Journal
Background: The measurement of the serum concentration of fibroblast growth factor-23 (FGF-23) is beginning to be used as a diagnostic tool in renal phosphate wasting disorders. Having observed an increased serum FGF-23 in three subjects with low circulating ferritin concentrations we investigated the association between low ferritin and raised serum FGF-23. Methods: We measured FGF-23 in 150 random anonymized serum samples with ferritin concentrations between <5 and 50 μg/L using three commercially available enzyme-linked immunosorbent assay (ELISA) kits. One kit, Human FGF-23[C-term] (Immutopics Inc, USA) measures total FGF-23 whereas the other two kits, Immutopics intact and FGF-23 ELISA (Kainos, Japan) are reported to measure only the biologically active intact molecule. Results: We have detected a significant inverse correlation of -0.565 (P<0.0001) between serum ferritin when <50 μg/L and FGF-23 using the C-terminal assay. This relationship is also shown with the Immutopics intact assay but is not demonstrated with the Kainos intact assay. Conclusion: The measurement of FGF-23 by both Immutopics assays is altered in the presence of low circulating concentrations of serum ferritin whereas with the Kainos intact assay this effect was not demonstrated. Serum ferritin should be measured when an elevated FGF-23 is obtained using the Immutopics C-terminal or intact FGF-23 assay to prevent misdiagnosis of the cause of this abnormality.


Related Articles

  • Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation. Eser, Baris; Yayar, Ozlem; Buyukbakkal, Mehmet; Erdogan, Bulent; Ercan, Zafer; Merhametsiz, Ozgur; haspulat, Ayhan; Gök Oğuz, Ebru; Dogan, İbrahim; Canbakan, Basol; Deniz Ayli, M. // Nefrologia;sep/oct2015, Vol. 35 Issue 5, p465 

    Background: Fibroblast growth factor 23 (FGF-23) is a phosphorus-regulating hormone. In chronic kidney disease (CKD), circulating FGF-23 levels are markedly elevated and independently associated with mortality. Left ventricular hypertrophy (LVH) is a potent risk factor for mortality in CKD, and...

  • Fibroblast growth factor 23. Smith, Edward R; McMahon, Lawrence P; Holt, Stephen G // Annals of Clinical Biochemistry;Mar2014, Vol. 51 Issue 2, p203 

    There is growing interest in the role of fibroblast growth factor 23 (FGF23) in various diseases of disordered mineral metabolism. In chronic kidney disease (CKD), where biochemical evidence of mineral disturbances is especially common, FGF23 measurement has been advocated as an early and...

  • The Association of Fibroblast Growth Factor 23 with Arterial Stiffness and Atherosclerosis in Patients with Autosomal Dominant Polycystic Kidney Disease. Coban, Melahat; Inci, Ayca; Yılmaz, Ustun; Asilturk, Emre // Kidney & Blood Pressure Research;Sep2018, Vol. 43 Issue 4, p1160 

    Background/Aims: In patients with autosomal dominant polycystic kidney disease (ADPKD), cardiovascular events are the most frequent cause of mortality and morbidity. The aim of our study is to investigate the association between serum fibroblast growth factor-23 (FGF-23) and arterial stiffness...

  • Diurnal variation and short-term pre-analytical stability of serum soluble α-klotho in healthy volunteers: a pilot study. Tan, Sven-Jean; Smith, Edward R; Hewitson, Tim D; Holt, Stephen G; Toussaint, Nigel D // Annals of Clinical Biochemistry;Jul2015, Vol. 52 Issue 4, p506 

    The article offers information on a case study wherein diurnal variability and stability of klotho gene, a transmembrane gene protein in serum was monitored using Enzyme-linked immunosorbent assay (ELISA). Topics discussed include content klotho protein responsible for renal diseases, collected...

  • Mapping of the Sites Responsible for Factor I-Cofactor Activity for Cleavage of C3b and C4b on Human C4b-Binding Protein (C4bp) by Deletion Mutagenesis1. Fukui, Aya; Yuasa-Nakagawa, Tomoko; Murakami, Yusuke; Funami, Kenji; Kishi, Natue; Matsuda, Tadashi; Fujita, Teizo; Seya, Tsukasa; Nagasawa, Shigeharu // Journal of Biochemistry;2002, Vol. 132 Issue 5, p719 

    Human C4b-binding protein (C4bp) facilitates the factor I-mediated proteolytic cleavage of the active forms of complement effectors C3b and C4b into their inactive forms. C4bp comprises a disulfide-linked heptamer of α-chains with complement (C) regulatory activity and a β-chain. Each...

  • A preliminary study on the application of PspA as a carrier for group A meningococcal polysaccharide. Wang, Lichan; Tan, Yajun; Wei, Chen; Zhang, Huajie; Luo, Peng; Zhang, Shumin; Ma, Xiao // PLoS ONE;7/10/2019, Vol. 14 Issue 7, p1 

    This study aimed to explore the feasibility of pneumococcal surface protein A (PspA) as a carrier protein. Three recombinant pneumococcal surface proteins from three different clades were expressed by the prokaryotic expression system and conjugated to group A meningococcal polysaccharide (GAMP)...

  • Markers of HTLV-III in patients with end stage renal failure treated by haemodialysis. Goldman, Michel; Liesnard, Corinne; Vanherweghem, Jean-Louis; Dolle, Nicole; Toussaint, Charles; Sprecher, Suzy; Cougniaux, Jacqueline // British Medical Journal (Clinical Research Edition);7/19/1986, Vol. 293 Issue 6540, p161 

    Examines the effects of hemodialysis on the markers of human T cell lymphotropic virus (HTLV) type-III in patients with end stage renal failure. Risk factors of AIDS; Derivation of the nosocomial transmission of HTLV-III; Use of enzyme linked immunosorbent assay in determining seropositive patient.

  • Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy. Sachiko Shimozato; Yoshiyuki Hiki; Hiroko Odani; Kazuo Takahashi; Kouichiro Yamamoto; Satoshi Sugiyama // Nephrology Dialysis Transplantation;Jun2008, Vol. 23 Issue 6, p1931 

    Background. Immunoglobulin A nephropathy (IgAN) is characterized by an aberrant structure of O-glycans in the IgA1 hinge region. Recently, under-galactosylated IgA1 has been found to be increased in Caucasian IgAN patients. Thus, we examined this in Japanese IgAN patients. Methods. An...

  • Controlled Release of Fibroblast Growth Factor 2 Stimulates Bone Healing in an Animal Model of Diabetes Mellitus. Santana, Ronaldo B.; Trackman, Philip C. // International Journal of Oral & Maxillofacial Implants;Sep/Oct2006, Vol. 21 Issue 5, p711 

    Purpose: Bone formation and the healing of calvarial defects in mice is diminished in chemically induced type 1 diabetes. The present study investigated whether controlled local release of fibroblast growth factor 2 (FGF-2) stimulates bone defect healing in this model of diabetes. Materials and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics